Willem A. Mak , Wendy Visser , Johannes G.M. Koeleman , David S.Y. Ong
{"title":"SARS-CoV-2 特异性 T 细胞反应:QuantiFERON SARS-CoV-2、T-SPOT.COVID 和内部 Omicron ELISpot 之间的比较分析。","authors":"Willem A. Mak , Wendy Visser , Johannes G.M. Koeleman , David S.Y. Ong","doi":"10.1016/j.jviromet.2024.114949","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>T cell immunity plays a pivotal role in mitigating the severity of coronavirus disease 2019 (COVID-19). Therefore, reliable functional T cell assays are required to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell immunity in specific patient populations.</p></div><div><h3>Methods</h3><p>We recruited a cohort of 23 healthcare workers who received their bivalent Omicron BA.1 / ancestral mRNA booster vaccination or were infected with the Omicron variant at a median of 144 days and 227 days before blood collection, respectively. In this cohort, we compared the performances of two widely utilized commercial SARS-CoV-2 interferon-gamma release assays (IGRAs), i.e., QuantiFERON SARS-CoV-2 and T-SPOT.<em>COVID</em>, and an in-house designed Omicron enzyme-linked immunospot (ELISpot).</p></div><div><h3>Results</h3><p>The QuantiFERON SARS-CoV-2 and T-SPOT.<em>COVID</em> assays detected SARS-CoV-2 spike-specific T cells in 34.8 % and 21.7 % of participants, respectively. Moreover, our in-house designed ELISpot that included Omicron BA.4 and BA.5 full-spike peptides detected T cell responses in 47.8 % of participants and was strongly associated with the T-SPOT.<em>COVID.</em></p></div><div><h3>Conclusion</h3><p>The evaluation of SARS-CoV-2 T cell immunity using commercially accessible assays may yield disparate outcomes as results from different assays are not directly comparable. A specific Omicron ELISpot should be considered to assess Omicron-specific T cell immunity.</p></div>","PeriodicalId":17663,"journal":{"name":"Journal of virological methods","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0166093424000739/pdfft?md5=90a8f097726be517e6b2f351bcc8d20d&pid=1-s2.0-S0166093424000739-main.pdf","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2-specific T cell responses: a comparative analysis between QuantiFERON SARS-CoV-2, T-SPOT.COVID, and an in-house Omicron ELISpot\",\"authors\":\"Willem A. Mak , Wendy Visser , Johannes G.M. Koeleman , David S.Y. Ong\",\"doi\":\"10.1016/j.jviromet.2024.114949\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>T cell immunity plays a pivotal role in mitigating the severity of coronavirus disease 2019 (COVID-19). Therefore, reliable functional T cell assays are required to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell immunity in specific patient populations.</p></div><div><h3>Methods</h3><p>We recruited a cohort of 23 healthcare workers who received their bivalent Omicron BA.1 / ancestral mRNA booster vaccination or were infected with the Omicron variant at a median of 144 days and 227 days before blood collection, respectively. In this cohort, we compared the performances of two widely utilized commercial SARS-CoV-2 interferon-gamma release assays (IGRAs), i.e., QuantiFERON SARS-CoV-2 and T-SPOT.<em>COVID</em>, and an in-house designed Omicron enzyme-linked immunospot (ELISpot).</p></div><div><h3>Results</h3><p>The QuantiFERON SARS-CoV-2 and T-SPOT.<em>COVID</em> assays detected SARS-CoV-2 spike-specific T cells in 34.8 % and 21.7 % of participants, respectively. Moreover, our in-house designed ELISpot that included Omicron BA.4 and BA.5 full-spike peptides detected T cell responses in 47.8 % of participants and was strongly associated with the T-SPOT.<em>COVID.</em></p></div><div><h3>Conclusion</h3><p>The evaluation of SARS-CoV-2 T cell immunity using commercially accessible assays may yield disparate outcomes as results from different assays are not directly comparable. A specific Omicron ELISpot should be considered to assess Omicron-specific T cell immunity.</p></div>\",\"PeriodicalId\":17663,\"journal\":{\"name\":\"Journal of virological methods\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0166093424000739/pdfft?md5=90a8f097726be517e6b2f351bcc8d20d&pid=1-s2.0-S0166093424000739-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of virological methods\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0166093424000739\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of virological methods","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0166093424000739","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
摘要
背景:T细胞免疫在减轻2019年冠状病毒疾病(COVID-19)的严重程度方面发挥着关键作用。因此,需要可靠的功能性 T 细胞检测来评估特定患者群体中严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)特异性 T 细胞免疫:我们招募了23名医护人员,他们分别在采血前144天和227天接受了二价奥米克龙BA.1/祖先mRNA强化疫苗接种或感染了奥米克龙变体。在这个队列中,我们比较了两种广泛使用的商用 SARS-CoV-2 干扰素-γ 释放测定(IGRA),即 QuantiFERON SARS-CoV-2 和 T-SPOT.COVID,以及内部设计的 Omicron 酶联免疫斑点(ELISpot)的性能:结果:QuantiFERON SARS-CoV-2和T-SPOT.COVID检测方法分别在34.8%和21.7%的参与者中检测到了SARS-CoV-2尖峰特异性T细胞。此外,我们自行设计的包含 Omicron BA.4 和 BA.5 全尖峰肽的 ELISpot 能检测到 47.8% 参与者的 T 细胞应答,并与 T-SPOT.COVID 检测结果密切相关:结论:使用市场上可买到的检测方法评估 SARS-CoV-2 T 细胞免疫力可能会产生不同的结果,因为不同检测方法的结果不能直接比较。应考虑使用特定的奥米克龙 ELISpot 来评估奥米克龙特异性 T 细胞免疫。
SARS-CoV-2-specific T cell responses: a comparative analysis between QuantiFERON SARS-CoV-2, T-SPOT.COVID, and an in-house Omicron ELISpot
Background
T cell immunity plays a pivotal role in mitigating the severity of coronavirus disease 2019 (COVID-19). Therefore, reliable functional T cell assays are required to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell immunity in specific patient populations.
Methods
We recruited a cohort of 23 healthcare workers who received their bivalent Omicron BA.1 / ancestral mRNA booster vaccination or were infected with the Omicron variant at a median of 144 days and 227 days before blood collection, respectively. In this cohort, we compared the performances of two widely utilized commercial SARS-CoV-2 interferon-gamma release assays (IGRAs), i.e., QuantiFERON SARS-CoV-2 and T-SPOT.COVID, and an in-house designed Omicron enzyme-linked immunospot (ELISpot).
Results
The QuantiFERON SARS-CoV-2 and T-SPOT.COVID assays detected SARS-CoV-2 spike-specific T cells in 34.8 % and 21.7 % of participants, respectively. Moreover, our in-house designed ELISpot that included Omicron BA.4 and BA.5 full-spike peptides detected T cell responses in 47.8 % of participants and was strongly associated with the T-SPOT.COVID.
Conclusion
The evaluation of SARS-CoV-2 T cell immunity using commercially accessible assays may yield disparate outcomes as results from different assays are not directly comparable. A specific Omicron ELISpot should be considered to assess Omicron-specific T cell immunity.
期刊介绍:
The Journal of Virological Methods focuses on original, high quality research papers that describe novel and comprehensively tested methods which enhance human, animal, plant, bacterial or environmental virology and prions research and discovery.
The methods may include, but not limited to, the study of:
Viral components and morphology-
Virus isolation, propagation and development of viral vectors-
Viral pathogenesis, oncogenesis, vaccines and antivirals-
Virus replication, host-pathogen interactions and responses-
Virus transmission, prevention, control and treatment-
Viral metagenomics and virome-
Virus ecology, adaption and evolution-
Applied virology such as nanotechnology-
Viral diagnosis with novelty and comprehensive evaluation.
We seek articles, systematic reviews, meta-analyses and laboratory protocols that include comprehensive technical details with statistical confirmations that provide validations against current best practice, international standards or quality assurance programs and which advance knowledge in virology leading to improved medical, veterinary or agricultural practices and management.